Biom’up Expands Management Team
2.9.2020 14:00:00 EEST | Business Wire | Press release
Biom’up France SAS and its affiliates (together, “Biom’up”), a leading developer of hemostatic products used in the surgical channel, currently featuring HEMOBLAST™ Bellows, today announced the appointment of Stéphanie Boileau-Canu as Chief Financial Officer and Emmanuel Zylber as Chief Scientific Officer. Ms. Boileau-Canu and Mr. Zylber will serve on the Company’s executive committee, reporting directly to Biom’up Group CEO, Patrice Ferrand.
Ms. Boileau-Canu brings deep financial expertise, gained across more than two decades in a diverse array of executive finance positions, including with SEB Group and several privately held companies. Mr. Zylber is a well-regarded technology and innovation executive, with vast R&D and product development experience, particularly within the medical device space.
Patrice Ferrand, Group CEO of Biom’up, said, “We are most pleased to welcome Stéphanie and Emmanuel to our management team at this very exciting time in our company’s evolution. Stéphanie and Emmanuel bring deep and complementary skills that will empower Biom’up to further expand upon our position in the highly valued hemostat market. We look forward to updating the medical community on a host of exciting near-term milestones, including clinical developments and geographic expansion.”
Additional Biographic Information
In nearly two decades at SEB Group, Ms. Boileau-Canu worked across several continents, in various finance-oriented leadership positions. During her career, she has also served a number of family-owned SMEs, first at Everial and then at Implid. Ms. Boileau-Canu received undergraduate and master’s degrees from IAE Dijon and an MBA from Emylon Business School.
Mr. Zylber is a proven and well-respected R&D leader. He has vast experience in product development and registration in the medical device industry, particularly the fields of spine/orthopedics, single-use medical and surgical products. With an entrepreneurial spirit, Mr. Zylber has worked at large, global companies such as Zimmer and Vygon, and private investment backed organizations such as Scient’X and Biomodex. He has a demonstrated track record or successfully working with the FDA, European and other international regulatory authorities. Mr. Zylber received his M.Sc. in Mechanical Engineering and Manufacturing Systems from Ecole Nationale d’Ingénieurs de Tarbes – ENIT.
About Biom’up
Founded in 2005 and based in the Lyon suburb of Saint-Priest (France), Biom’up develops and commercializes hemostatic products based on patented biopolymers designed to simplify surgeons’ practices for open and minimally invasive surgical procedures across multiple specialties such as cardiac, general, and orthopedic surgery. The Company’s lead product, HEMOBLAST™ Bellows and its laparoscopic applicator are marketed in Europe and the United States.
About HEMOBLAST™
HEMOBLAST™ Bellows is a hemostatic product used to control bleeding in a broad range of open and minimally invasive surgical procedures, including laparoscopy.
Uncontrolled bleeding is a major surgical complication associated with higher mortality, longer hospitalization and higher rates of transfusions and reoperations. Beyond its impact on patient’s health, this major complication causes excess costs in all surgical specialties and is a burden for hospital budgets across the globe. HEMOBLAST™ Bellows is the only surgical hemostatic agent approved by the FDA based on the validated SPOT GRADE™ Surface Bleeding Severity Scale (SBSS), which demonstrates the ability to control a range of bleeding from minimal (oozing), mild (pooling) and moderate (flowing) bleeding. HEMOBLAST™ Bellows is proven to control bleeding with flow rates up to 117 mL per minute. Due to its efficacy, versatility and ease of use, HEMOBLAST™ Bellows is quickly becoming a popular choice amongst U.S. and European surgeons looking for new options to control surgical bleeding challenges.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200902005289/en/
Contact information
Media:
For the United States:
Daniel Yunger
Kekst CNC
+1 212-521-4800
daniel.yunger@kekstcnc.com
For France:
Elvira Pignal
Kekst CNC
+33 6 36 23 68 36
elvira.pignal@kekstcnc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Spatial Announces Release 2027 1.0 with New Enhancements Across CAD Modeling, Interoperability, Data Preparation, and Meshing17.11.2026 21:10:00 EET | Press release
Spatial Corp., the leading software development kit provider for design, manufacturing and engineering solutions and a subsidiary of Dassault Systèmes, today announced the availability of its 2027 1.0 Release. This latest release introduces new capabilities and enhancements across Spatial's 3D ACIS Modeler, CGM Modeler, 3D InterOp, Data Prep and CSM/CVM product lines. Designed to improve efficiency, flexibility and robustness across CAD modeling, interoperability, data preparation and simulation workflows, the release delivers enhanced geometry processing, expanded modeling capabilities, improved CAD translation and advances in mesh generation for a better workflow coverage. 3D ACIS Modeler Enhanced Blending (Filleting) The 3D ACIS Modeler introduces support for asymmetric fixed-width blends with a conic cross-section, providing users with finer control over smooth transitions between edges. This enhancement builds on the symmetric fixed-width blend with a conic cross-section capabilit
Global EV Alliance Survey: EV Drivers Identify Myths and Misconceptions as the Biggest Barrier to Adoption17.11.2026 20:00:00 EET | Press release
Myths and misconceptions about electric cars, from battery lifespan and fire risk to grid collapse, are the biggest barrier to EV adoption, according to respondents to the annual Global EV Driver Survey. The 2026 survey draws on responses from more than 29,500 EV drivers across 34 countries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117539716/en/ MYTHS. Battery lifespan (72%), fire risk (58%) and grid collapse (45%) top the list of EV myths reported by respondents to the 2026 Global EV Driver Survey, which gathered responses from more than 29,500 EV drivers across 34 countries. “The EV transition is not just an infrastructure or affordability challenge. It is also an information challenge. Outdated information and misconceptions continue to influence decisions long after the technology has moved on,” says Ellen Hiep, from the Steering Committee of the Global EV Alliance (GEVA). Myths the greatest barrier Asked to ide
KILL Trulioo’s Global Risk Platform Unlocks Device and Behavioral Intelligence Via Bureau Partnership17.11.2026 20:00:00 EET | Press release
Trulioo requests that their press release NewsItemId: 20261117163539 “Trulioo’s Global Risk Platform Unlocks Device and Behavioral Intelligence Via Bureau Partnership” be killed. The release was issued in error by Trulioo.
TreeFrog Therapeutics Appoints James Sterling as Chief Financial Officer17.11.2026 19:04:00 EET | Press release
TreeFrog Therapeutics, a biotechnology company developing scalable cell therapies built on its proprietary C-Stem™ technology, today announced the appointment of James Sterling as Chief Financial Officer, effective November 1, 2026. James joins TreeFrog’s executive leadership team and reports to Mark Rothera, President and Chief Executive Officer. He oversees finance, investor relations and corporate development as the company enters its next phase of growth. “I am delighted to welcome James to TreeFrog. James brings a valuable combination of biotech CFO and Wall Street experience that supports our ambitions to develop TreeFrog into a key enabling partner and drug developer in the regenerative medicines field,” said Mark Rothera, President and Chief Executive Officer of TreeFrog Therapeutics. James contributes deep experience in corporate finance, capital markets and strategic planning across therapeutics and diagnostics. Recently, he served as Chief Financial Officer of Bluebird Bio (
Visa Report: AI-Enabled Fraud and Third-Party Attacks Are Scaling Worldwide17.11.2026 17:40:00 EET | Press release
Fraud is becoming more automated, targeted and global as criminals use AI to exploit weak points across the payments ecosystem and target third-party providers that can provide access to multiple downstream payment organizations, according to the Visa (NYSE: V) Fall 2026 Biannual Threats Report released today during International Fraud Awareness Week. Developed by Visa Payment Ecosystem Risk and Control (PERC), the report examines threat activity observed between January and June 2026 and finds that AI is not creating entirely new categories of fraud. Instead, it is helping criminals that execute existing attacks faster, at greater scale, and with greater precision, while increasingly targeting third-party providers that can provide access to multiple downstream organizations at once. Although attack volumes increased in several areas, the report also found evidence that coordinated, network-level defenses are reducing the impact of these threats. “AI is changing the economics of fraud
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
